Cefotetan in complicated urinary tract infections--clinical experience.
Cefotetan was evaluated to determine the efficacy and safety of a 1 g dose administered intravenously twice daily in the treatment of complicated urinary tract infections (UTI). Sixty patients entered and 58 patients completed the study. Duration of treatment ranged from 7 to 16 days with a mean of 10.1 days. A satisfactory clinical response was observed in 85%. Eradication of the infecting organisms was prompt and complete in 45 patients. Relapse, reinfection or superinfection occurred in seven patients and in six patients the infecting organisms did not respond to treatment. Cefotetan was well tolerated but two patients had treatment withdrawn because of macular rash. It is concluded that cefotetan is highly effective in treating complicated UTIs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D015313:Cefotetan; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D015313:Cefotetan